Dimethylfumarate Attenuates Renal Fibrosis via NF-E2-Related Factor 2-Mediated Inhibition of Transforming Growth Factor-β/Smad Signaling

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Oh, Chang Joo ^a   Kim, Joon Young ^a,b   Choi, Young Keun ^a   Kim, Han Jong ^a,c   Jeong, Ji Yun ^a   Bae, Kwi Hyun ^a   Park, Keun Gyu ^a   Lee, In Kyu ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b Gwangju Institute of Science and Technology (GIST)   (South Korea)

^c Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; DIMETHYLFUMARATE; FIBRONECTIN; FUMARIC ACID ETHYL ESTER; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SMAD PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL LEVEL; CELL NUCLEUS; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; KIDNEY CELL; KIDNEY FIBROSIS; MESANGIUM CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; URETER OBSTRUCTION;

ACTINS; ANIMALS; BLOTTING, WESTERN; CELL LINE; COLLAGEN TYPE I; FIBRONECTINS; FIBROSIS; FUMARATES; HEK293 CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH; NF-E2-RELATED FACTOR 2; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84867324847     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045870     Document Type: Article

References (45)

1. Schieppati A, Remuzzi G, (2005) Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications. Kidney Int 68 (Suppl 1) (): S7-S10.
2. Youhua Liu, (2006) Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 69: 213-217.
3. Border WA, Noble NA, (1994) Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292.
4. Johnson RJ, Floege J, Couser WG, Alpers CE, (1993) Role of platelet derived growth factor in glomerular disease. J Am Soc Nephrol 4: 119-128.
5. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, et al. (2001) Aminoguanidine Ameliorates Overexpression of Prosclerotic Growth Factors and Collagen Deposition in Experimental Diabetic Nephropathy. J Am Soc Nephrol 12: 2098-2107.
6. Border WA, Noble NA, (1977) TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 51: 1388-96.
7. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW, (1995) ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidnet Int 47: 1039-47.
8. Ha H, Lee HB, (2003) Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 14: 246-9.
9. Klahr S, Morrissey J, (2002) Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 283: F861-75.
10. Gagliardini E, Benigni A, (2006) Role of anti-TGF-β antibodies in the treatment of renal injury. Cytokine & Growth Factor Rev 17: 89-96.
11. Mrowietz U, Asadullah K, (2005) Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med 11: 43-8.
12. Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH, (2010) Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study. Br J Dermatol 162 (2) (): 427-34.
13. Ockenfels HM, Schultewolter T, Ockenfels G, Funk R, Goos M, (1998) The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. British Journal of Dermatology 139: 390-395.
14. Gold R, Linker RA, Stangel M, (2012) Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 142: 44-8.
15. Gold R, (2011) Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 25: 37-52.
16. Papadopoulou A, D'Souza M, Kappos L, Yaldizli O, (2010) Dimethyl fumarate for multiple sclerosis. Expert Opin Investig Drugs 19: 1603-12.
17. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, et al. (2010) Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation 7: 30.
18. Moharregh-Khiabani D, Linker RA, Gold R, Stangel M, (2009) Fumaric Acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol 7: 60-4.
19. Valero T, Steele S, Neumüller K, Bracher A, Niederleithner H, et al. (2010) Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis. J Invest Dermatol 130: 1087-94.
20. Yamazoe Y, Tsubaki M, Matsuoka H, Satou T, Itoh T, et al. (2009) Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biol Int 33: 1087-94.
21. Loewe R, Valero T, Kremling S, Pratscher B, Kunstfeld R, et al. (2006) Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res 66: 11888-96.
22. Seidel P, Goulet S, Hostettler K, Tamm M, Roth M, (2010) DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1. Respir Res 11: 145.
23. Ellrichmann G, Petrasch-Parwez E, Lee DH, Reick C, Arning L, et al. (2011) Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS ONE 6: e16172.
24. Lin SX, Lisi L, Russo CD, Polak PE, Sharp A, et al. (2011) The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 3: e00055.
25. Schmidt TJ, Ak M, Mrowietz U, (2007) Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine-preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem 15: 333-42.
26. Jung KA, Kwak MK, (2010) The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 15: 7266-91.
27. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, et al. (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134: 678-92.
28. Aleksunes LM, Manautou JE, (2007) Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease. Toxicol Pathol 35: 459-73.
29. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, et al. (2010) The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59: 850-60.
30. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, et al. (2010) Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J Pharmacol Exp Ther 335: 2-12.
31. Shin DH, Park HM, Jung KA, Choi HG, Kim JA, et al. (2010) The NRF2-heme oxygenase-1 system modulates cyclosporin A-induced epithelial-mesenchymal transition and renal fibrosis. Free Radic Biol Med 48: 1051-63.
32. Tsai PY, Ka SM, Chao TK, Chang JM, Lin SH, et al. (2011) Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice. Free Radic Biol Med 50: 1503-16.
33. Oh CJ, Kim JY, Min AK, Park KG, Harris RA, et al. (2012) Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. Free Radic Biol Med 52: 671-82.
34. Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, et al. (2010) p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 285: 22576-91.
35. Sato S, Kawamura H, Takemoto M, Maezawa Y, Fujimoto M, et al. (2009) Halofuginone prevents extracellular matrix deposition in diabetic nephropathy. Biochem Biophys Res Commun 379: 411-6.
36. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A, (2003) Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112: 1486-94.
37. Zhou A, Ueno H, Shimomura M, Tanaka R, Shirakawa T, et al. (2003) Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int 64: 92-101.
38. Hwang M, Kim HJ, Noh HJ, Chang YC, Chae YM, et al. (2006) TGF-beta 1 siRNA suppresses the tubulointerstitial fibrosis in the kidney of ureteral obstruction. Exp Mol Pathol 41: 48-54.
39. Barnes JL, Gorin Y, (2011) Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidase. Kidney Int 79: 944-56.
40. Jiang Z, Seo JY, Ha H, Lee EA, Kim YS, et al. (2003) Reactive oxygen species mediate TGF-beta1-induced plasminogen activator inhibitor-1 upregulation in mesangial cells. Biochem Biophys Res Commun 309: 961-6.
41. Iglesias-De La Cruz MC, Ruiz-Torres P, Alcamí J, Díez-Marqués L, Ortega-Velázquez R, et al. (2001) Hydrogen peroxide increases extracellular matrix mRNA through TGF-beta in human mesangial cells. Kidney Int 59: 87-95.
42. Cross SA, Cook DR, Chi AW, Vance PJ, Kolson LL, et al. (2011) Dimethyl Fumarate, an Immune Modulator and Inducer of the Antioxidant Response, Suppresses HIV Replication and Macrophage-Mediated Neurotoxicity: A Novel Candidate for HIV Neuroprotection. J Immunol 187: 5015-5025.
43. Correa-Costa M, Semedo P, Monteiro AP, Silva RC, Pereira RL, et al. (2010) Induction of heme oxygenase-1 can halt and even reverse renal tubule-interstitial fibrosis. PLoS ONE 5: e14298.
44. Kim HJ, Kim JY, Lee SJ, Kim HJ, Oh CJ, et al. (2010) α-Lipoic acid prevents neointimal hyperplasia via induction of p38 mitogen-activated protein kinase/Nur77-mediated apoptosis of vascular smooth muscle cells and accelerates postinjury reendothelialization. Arterioscler Thromb Vasc Biol 30: 2164-72.
45. Jung GS, Kim MK, Jung YA, Kim HS, Park IS, et al. (2012) Clusterin attenuates the development of renal fibrosis. J Am Soc Nephrol 23 (1) (): 73-85.